查詢結果分析
來源資料
相關文獻
- Antianginal and Anti-Ischemic Efficacy of Nisoldipine in Stable Angina Pectoris: A Randomized, Double-Blind, Placebo-Controlled Trial
- Amlodipine對穩定性心絞痛病人之療效
- 血管收縮素轉化酶抑制劑在糖尿病病人的使用
- 鈣離子阻斷劑對兔子肌筋膜引痛點自發性電位之影響
- 鈣離子阻斷劑於心肌梗塞之治療
- 從ABCD及FACET臨床試驗談鈣離子阻斷劑在糖尿病病人的使用
- 鈣離子阻斷劑
- 性交頭痛
- Unilateral Gynecomastia and Lung Cancer--A Case Report
- Ambiguity between Acute Myocardial Infarction and Coronary Artery Spasm: A Case Report and Review of the Literature
頁籤選單縮合
題名 | Antianginal and Anti-Ischemic Efficacy of Nisoldipine in Stable Angina Pectoris: A Randomized, Double-Blind, Placebo-Controlled Trial=Nisoldipine治療穩定性心絞痛患者療效之評估:雙盲隨機與安慰劑對照之研究 |
---|---|
作者 | 陳嬰華; 劉如濟; 王石補; Chen, Ying-hwa; Liu, Ru-chi; Wang, Shih-pu; |
期刊 | 中華醫學雜誌 |
出版日期 | 19961100 |
卷期 | 58:5 1996.11[民85.11] |
頁次 | 頁323-328 |
分類號 | 415.3161 |
語文 | eng |
關鍵詞 | 鈣離子阻斷劑; 穩定性心絞痛; Calcium channel blocker; Nisoldipine; Stable angina pectoris; |
中文摘要 | 背景 Nisoldipine為第二代鈣離子阻斷劑,具有強力擴張血管的作用, 且對於冠狀動脈平滑肌有極高度之選擇性。本研究目的在評估每日一次 Nisoldipine,治療穩定性心絞痛患者之療效。 方法 本研究共有三十三位穩定性心絞痛患者,在停用其他治療心絞痛之藥物 後,先給予四天之安慰劑,讓先前服用之藥物代謝後,再雙盲隨機進入治療組 (每日服用Nisoldipine 10mg一次)與對照組(每日服用安慰劑一次)服藥六天。 每位患者在第四天及第十天時,均各接受三次運動心電圖測試。分別於服藥前、 服藥二小時及六小時後進行。 結果 二十八位患者完成研究(十四位服用Nisoldipine,十四位服用安慰劑), 進入統計分析。與對照組比較,我們發現Nisoldipine 10mg一天一次,有效地增 長病患的運動時間及減少心絞痛發作的頻率。另外,服用Nisoldipine之病患消 耗舌下硝化甘油的次數,亦有減低的趨勢。治療組患者中僅有二人主訴輕微不 適(一人為胃部不適,另一人為臉部泛紅及心悸)。 結論 Nisoldipine 10mg一天一次可有效治療心肌缺氧,增加運動耐量,無明顯 的副作用。且其治療心肌缺氧的作用可持續六小時以上。 |
英文摘要 | Background. Nisoldipine, a dihydropyridine calcium antagonist, is a potent vasodilator with selectivity for the coronary tree. The purpose of the study was to evaluate the onset and duration of antianginal and anti-ischemic efficacy of a single oral dose of nisoldipine compared with placebo in patients with stable angina pectoris. Methods. In 33 patients with stable angina pectoris, nisoldipine was tested (10 mg daily) in a randomized, double-blind, placebo-controlled study. Drugs having antianginal and anti-ischemic effects (except sublingual nitroglycerin) were withdrawn. Patients underwent a four-day "washout" phase, then were randomly assigned to nisoldipine (10 mg daily) or placebo for six days. On Day 4 and Day 10, three times of treadmill exercise testing were performed before daily medication was given, 2 hours and 6 hours after dosing, respectively. Results. Twenty-eight patients (14 taking nisoldipine and 14 taking placebos) completed the study and were included in the statistical evaluation. Compared with placebo, total exercise duration increased significantly during all three sequential exercise testing in patients receiving nisoldipine. The frequency of anginal attacks decreased significantly while patients were receiving nisoldipine (0.29 +/- 0.44/patient/day versus 0.14 +/- 0.26/patient/day, p < 0.05). Similarly, there was a trend toward a decrease in the consumption of sublingual nitroglycerin while patients were receiving nisoldipine. Adverse effects were mild. Conclusions. The study confirms that nisoldipine is an active antianginal and anti- ischemic agent, with an acceptable side effect profile when used as monotherapy. The anti-ischemic effect lasted more than six hours and the drug could be administered once daily. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。